(Bloomberg) – The CEO of Organigram Holdings Inc. warned that the industry would remain unpredictable until the last quarter of this year, even if the pot manufacturer’s stock was heading for the greatest profit ever.
Organization chart shares rose up to 50% in New York on Wednesday after sales in the first quarter of the fiscal year exceeded analysts’ highest estimates and adjusted Ebitda was positive again after a loss in the previous quarter. Investors are excited to see cannabis companies report profits that reward few and punish those who don’t.
Much of the sector followed a higher organizational chart, with Hexo Corp. up 17%, Aurora Cannabis Inc. up 15%, Cronos Group Inc. up 8.2% and Aphria Inc. up 8%.
However, it will still be a few quarters before the industry can achieve predictable results, said CEO Greg Engel.
“I still think we won’t develop a sense of normalcy or predictability by the fourth quarter of this year,” Engel said in a phone interview.
One of the biggest unknowns is how Canada’s launch of new legal products like Vapes and Edibles will go. Engel said Organigram had already seen provinces submit reorders for their vapes that hit the shelves on December 17, and one province tripled its original order for Organigram’s chocolates, which will be sold later this quarter.
The company acquired a high-performance chocolate production line in October and would be ready to do white label production for other companies, Engel said.
Organizational chart will continue to sell cannabis to third parties, he said. The company had unexpected wholesale sales of $ 9.2 million in the first quarter as competitors were willing to pay for high quality products. This was the main reason why it was able to exceed sales estimates.
“We have had several companies that rely more on this model both as a strategy and in the near future, and we saw it as an opportunity to diversify,” he said.
Analysts praised the quarter and said Organigram was one of the better positioned Canadian pot producers.
“We are pleasantly surprised that Organigram exceeds our estimates, as do those of the street. Organigram has successfully overcome the obstacles in the industry that some of its competitors have violently encountered,” said Rahul Sarugaser, an analyst at Raymond James, when he said the stock improved to outperform the market. “We believe there is a clear sky on the horizon of Organigram.”
(Updates share motion in the second paragraph, adds industrial moves in the third paragraph)
To the reporters about this story: Kristine Owram in New York at [email protected]
For contact with the editors responsible for this story: Brad Olesen at [email protected], Steven Fromm
<p class = "Canvas-Atom Canvas-Text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "For more articles like this please visit us at bloomberg.com“data-reactid =” 41 “> You can find more items of this kind at bloomberg.com
<p class = "canvas-atom canvas-text Mb (1,0em) Mb (0) – sm Mt (0,8em) – sm" type = "text" content = "Subscribe now “data-reactid =” 42 “> Subscribe now to stay ahead with the most trusted business news source.
© 2020 Bloomberg L.P.